MASTER: A Randomized, Double-Blinded, Controlled, Parallel Group, Non inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red blood Cells in Patients Undergoing Complex Cardiac Surgery Procedures (the ReCePI
|Effective start/end date||5/17/19 → 5/16/24|
- CERUS CORPORATION
- US DEPT OF HEALTH & HUMAN SERVICES PHE
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.